Shopping Cart
- Remove All
Your shopping cart is currently empty
Quinotolast sodium inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner in the concentration range of 1-100 μg/mL.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,650 | 8-10 weeks | |
| 50 mg | $2,150 | 8-10 weeks | |
| 100 mg | $3,100 | 8-10 weeks |
| Description | Quinotolast sodium inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner in the concentration range of 1-100 μg/mL. |
| In vitro | Quinotolast significantly inhibits PGD2 and LTC4 release. Quinotolast inhibits PGD2 release by 100% and LTC4 release by 54%. The inhibitory effect of Quinotolast on histamine release from dispersed lung cells is largely independent of the preincubation period, no tachyphylaxis being observed. Quinotolast shows a significant inhibition of inflammatory mediators from human dispersed lung cells[1]. |
| In vivo | Quinotolast is given i.v. to rats, Quinotolast, dose-dependently inhibits PCA. The doses of Quinotolast required to inhibit the reaction by 50% (ED50) is 0.0063 mg/kg. Given p.o.[2].Quinotolast potently inhibits such type I allergic reactions as passive cutaneous anaphylaxis (PCA) and anaphylactic bronchoconstriction in rats by both intravenous and oral dosing. |
| Synonyms | FR71021 |
| Molecular Weight | 371.312 |
| Formula | C17H12N6NaO3 |
| Cas No. | 101193-62-8 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.